Department of Radiation Oncology, University of Pennsylvania, 3400 Spruce Street/2 Doner Bldg., Philadelphia, PA 19104, USA.
Photodiagnosis Photodyn Ther. 2006 Dec;3(4):234-46. doi: 10.1016/j.pdpdt.2006.08.002. Epub 2006 Oct 19.
We provide a review of the current state of dosimetry in prostate photodynamic therapy (PDT). PDT of the human prostate has been performed with a number of different photosensitizers and with a variety of dosimetry schemes. The simplest clinical light dose prescription is to quantify the total light energy emitted per length (J/cm) of cylindrical diffusing fibers (CDF) for patients treated with a defined photosensitizer injection per body weight. However, this approach does not take into account the light scattering by tissue and usually underestimates the local light fluence rate, and consequently the fluence. Techniques have been developed to characterize tissue optical properties and light fluence rates in vivo using interstitial measurements during prostate PDT. Optical methods have been developed to characterize tissue absorption and scattering spectra, which in turn provide information about tissue oxygenation and drug concentration. Fluorescence techniques can be used to quantify drug concentrations and photobleaching rates of photosensitizers.
我们提供了一份关于前列腺光动力疗法(PDT)中剂量学的现状综述。已经使用了许多不同的光敏剂和各种剂量学方案来进行人类前列腺 PDT。最简单的临床光剂量处方是量化每个长度(J/cm)的圆柱形扩散光纤(CDF)发出的总光能,用于接受特定光敏剂注射的患者,按体重计算。然而,这种方法没有考虑到组织的光散射,通常会低估局部光强度,因此也会低估剂量。已经开发了一些技术,通过在前列腺 PDT 期间进行间质测量,来在体内对组织光学特性和光强度进行量化。已经开发了光学方法来对组织的吸收和散射光谱进行量化,这反过来又提供了关于组织氧合和药物浓度的信息。荧光技术可用于量化药物浓度和光敏剂的光漂白率。